2026年1月,尽管《医疗保险计划》的交易有所削减,但大多数名牌药品价格上升,凸显了目前承受能力方面的挑战。 In January 2026, most brand-name drugs rose in price, despite some cuts from Medicare deals, highlighting ongoing affordability challenges.

2026年1月,872种品牌药品价格上升,中位增长率为4%,尽管特朗普时代交易旨在降低成本,但价格仍呈年年上升趋势。 In January 2026, 872 brand-name drugs saw price increases, with a median rise of 4%, continuing a yearly trend despite Trump-era deals aimed at lowering costs. 虽然一些药物,包括胰岛素和糖尿病药物,由于 " 拜登-时代医疗保险 " 的谈判,可能出现大幅度削减,但许多公司,包括辉瑞公司,仍然以再投资和成本上升为由,提出清单价格。 While some drugs, including insulin and diabetes medications, saw significant cuts likely due to Biden-era Medicare negotiations, many companies—including Pfizer—still raised list prices, citing reinvestment and rising costs. 对病人的影响各有不同,因为保险退款可以抵消较高的清单价格,但自付费用和意外账单仍然很常见。 The impact on patients varies, as insurance rebates can offset higher list prices, but out-of-pocket costs and surprise bills remain common. 这一情况表明,在控制药物价格方面持续存在挑战,自愿协议对总体承受能力的影响有限。 The situation reveals persistent challenges in controlling drug prices, with voluntary agreements having limited effect on overall affordability.